10821809

Source:http://linkedlifedata.com/resource/pubmed/id/10821809

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0004153, umls-concept:C0014257, umls-concept:C0205178, umls-concept:C0205191, umls-concept:C0277785, umls-concept:C0597357, umls-concept:C0680242, umls-concept:C1555029
pubmed:issue	20
pubmed:dateCreated	2000-6-21
pubmed:abstractText	The renin-angiotensin system may contribute to atherogenesis through the promotion of endothelial dysfunction. The present study was performed to determine whether angiotensin-1 (AT(1)) receptor inhibition improves endothelial dysfunction.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0147763
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Acetylcholine, http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II, http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Losartan, http://linkedlifedata.com/resource/pubmed/chemical/Nitroprusside, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2, http://linkedlifedata.com/resource/pubmed/chemical/Vasodilator Agents
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	1524-4539
pubmed:author	pubmed-author:EllahhamSS, pubmed-author:MincemoyerRR, pubmed-author:PanzaJ AJA, pubmed-author:PrasadAA, pubmed-author:QuyyumiA AAA, pubmed-author:SchenkeW HWH, pubmed-author:Tupas-HabibTT, pubmed-author:WaclawinM AMA
pubmed:issnType	Electronic
pubmed:day	23
pubmed:volume	101
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2349-54
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:10821809-Acetylcholine, pubmed-meshheading:10821809-Angiotensin II, pubmed-meshheading:10821809-Angiotensin Receptor Antagonists, pubmed-meshheading:10821809-Arteriosclerosis, pubmed-meshheading:10821809-Brachial Artery, pubmed-meshheading:10821809-Endothelium, Vascular, pubmed-meshheading:10821809-Female, pubmed-meshheading:10821809-Femoral Artery, pubmed-meshheading:10821809-Humans, pubmed-meshheading:10821809-Hyperemia, pubmed-meshheading:10821809-Losartan, pubmed-meshheading:10821809-Male, pubmed-meshheading:10821809-Middle Aged, pubmed-meshheading:10821809-Nitroprusside, pubmed-meshheading:10821809-Receptor, Angiotensin, Type 1, pubmed-meshheading:10821809-Receptor, Angiotensin, Type 2, pubmed-meshheading:10821809-Regional Blood Flow, pubmed-meshheading:10821809-Single-Blind Method, pubmed-meshheading:10821809-Time Factors, pubmed-meshheading:10821809-Vascular Resistance, pubmed-meshheading:10821809-Vasodilation, pubmed-meshheading:10821809-Vasodilator Agents
pubmed:year	2000
pubmed:articleTitle	Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis.
pubmed:affiliation	Cardiology Branch, Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
pubmed:publicationType	Journal Article, Clinical Trial